Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc.verified

CRVS

Price:

$11.93

Market Cap:

$1.00B

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small...[Read more]

Industry

Biotechnology

IPO Date

2016-03-23

Stock Exchange

NASDAQ

Ticker

CRVS

The Enterprise Value as of June 2026 (TTM) for Corvus Pharmaceuticals, Inc. (CRVS) is 963.93M

According to Corvus Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 963.93M. This represents a change of 38.30% compared to the average of 696.98M of the last 4 quarters.

Corvus Pharmaceuticals, Inc. (CRVS) Historical Enterprise Value (quarterly & annually)

How has CRVS Enterprise Value performed in the past?

The mean historical Enterprise Value of Corvus Pharmaceuticals, Inc. over the last ten years is 150.91M. The current 963.93M Enterprise Value has changed 63.77% with respect to the historical average. Over the past ten years (40 quarters), CRVS's Enterprise Value was at its highest in in the March 2026 quarter at 1.28B. The Enterprise Value was at its lowest in in the December 2018 quarter at -7260510.00.

Quarterly (TTM)
Annual

Average

150.91M

Median

88.22M

Minimum

-13635300.00

Maximum

604.39M

Corvus Pharmaceuticals, Inc. (CRVS) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Corvus Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 334.85%

Maximum Annual Enterprise Value = 604.39M

Minimum Annual Increase = -1256.54%

Minimum Annual Enterprise Value = -13635300.00

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2025604.39M89.67%
2024318.65M334.85%
202373.28M152.58%
202229.01M-29.34%
202141.06M-54.78%
202090.80M-42.42%
2019157.70M-1256.54%
2018-13635300.00-111.16%
2017122.21M42.71%
201685.64M-70.13%

Corvus Pharmaceuticals, Inc. (CRVS) Average Enterprise Value

How has CRVS Enterprise Value performed in the past?

The current Enterprise Value of Corvus Pharmaceuticals, Inc. (CRVS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

332.11M

5-year avg

213.28M

10-year avg

150.91M

Corvus Pharmaceuticals, Inc. (CRVS) Enterprise Value vs. Peers

How is CRVS’s Enterprise Value compared to its peers?

Corvus Pharmaceuticals, Inc.’s Enterprise Value is greater than Olema Pharmaceuticals, Inc. (810.53M), less than Ventyx Biosciences, Inc. (982.56M), greater than Prothena Corporation plc (110.11M), greater than REGENXBIO Inc. (400.14M), greater than Akebia Therapeutics, Inc. (97.86M), greater than Verastem, Inc. (204.11M), greater than Gossamer Bio, Inc. (199.90M), less than KalVista Pharmaceuticals, Inc. (1.49B), less than Absci Corporation (1.06B), greater than Compass Therapeutics, Inc. (235.34M),

Build a custom stock screener for Corvus Pharmaceuticals, Inc. (CRVS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Corvus Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Corvus Pharmaceuticals, Inc. (CRVS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Corvus Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Corvus Pharmaceuticals, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Corvus Pharmaceuticals, Inc. (CRVS)?

What is the 3-year average Enterprise Value for Corvus Pharmaceuticals, Inc. (CRVS)?

What is the 5-year average Enterprise Value for Corvus Pharmaceuticals, Inc. (CRVS)?

How does the current Enterprise Value for Corvus Pharmaceuticals, Inc. (CRVS) compare to its historical average?